drugset / Trial / NCT00617565

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

NCT00617565

Phase 3 Completed 219 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.

Timeline

Start
2003-07-08
Primary completion
2003-11-26
Completion
2003-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic human insulin Protein / enzyme biologic
Subject biphasic insulin aspart Protein / enzyme biologic